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Abstract
With the availability of large‐scale biobanks, genome‐wide scale phenome‐wide
association studies are being instrumental in discovering novel genetic variants
associated with clinical phenotypes. As increasing number of such association
results from different biobanks become available, methods to meta‐analyse
those association results is of great interest. Because the binary phenotypes in
biobank‐based studies are mostly unbalanced in their case–control ratios, very
few methods can provide well‐calibrated tests for associations. For example,
traditional Z‐score‐based meta‐analysis often results in conservative or antic-
onservative Type I error rates in such unbalanced scenarios. We propose two
meta‐analysis strategies that can efficiently combine association results from
biobank‐based studies with such unbalanced phenotypes, using the saddlepoint
approximation‐based score test method. Our first method involves sharing the
overall genotype counts from each study, and the second method involves
sharing an approximation of the distribution of the score test statistic from each
study using cubic Hermite splines. We compare our proposed methods with a
traditional Z‐score‐based meta‐analysis strategy using numerical simulations
and real data applications, and demonstrate the superior performance of our
proposed methods in terms of Type I error control.
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1 | INTRODUCTION
Genome‐wide scale phenome‐wide association analysis
(Hebbring, 2014) is gaining increasing attention in
the human genetics community in the recent years. The
availability of detailed phenotypic information from the
electronic health record (EHR) systems in large biobanks
as well as the recent advancements in genotyping and
imputation technologies (Das et al., 2016) are allowing
researchers to phenotype thousands of traits and genotype
tens of millions of variants in large cohort studies. Several
biobank studies, including UK‐Biobank (Bycroft et al.,
2017), Michigan Genomics Initiative and Nord‐Trøndelag
Health Study (Krokstad et al., 2013) currently attempt to
test for associations in all genotype–phenotype pairs,
which results in billions of tests. These large‐scale analyses
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have great potential to find novel genotype–phenotype
associations, which will help uncover underlying mole-
cular mechanism of clinical phenotypes.
In a typical phenome‐wide association study (PheWAS)
in biobanks, most of the phenotypes are binary with
unbalanced (1:5) or often extremely unbalanced (1:500)
case–control ratios, which results in performing 1,000s of
unbalanced case–control genome‐wide association studies
(GWASs). For example, ~1,400 case–control studies in the
UK Biobank interim release data have more than 100
controls/case (see Histogram in Figure S1 in Supporting
Information Material A). Under such case–control imbal-
ance, the standard asymptotic tests such as the Wald test,
score test, and likelihood ratio test can severely inflate the
Type I errors resulting in several spurious associations,
especially for the low frequency (0.01 <minor allele
frequency [MAF] < 0.05) and rare (MAF< 0.01) variants
(Dey, Schmidt, Abecasis, & Lee, 2017; Ma, Blackwell,
Boehnke, Scott, & investigators, 2013). To obtain well‐
calibrated P values in such situations, Ma et al. (2013)
proposed to use the Firth’s penalised likelihood ratio test
(Firth, 1993). Since the Firth’s test is computationally too
expensive to be used for billions of association tests, Dey
et al. (2017) developed a fast saddlepoint approximation
(SPA)‐based score test, fastSPA, which is computationally
much faster than the Firth’s test.
As more and more association results from different
biobanks become available, meta‐analysing (Evangelou &
Ioannidis, 2013) the results from the unbalanced GWASs is
the logical next step to improve the power to detect novel
genotype–phenotype associations. Z‐score‐based approach
(Cooper, Hedges, & Valentine, 2009) which converts P values
to normal Z scores for combining multiple study P values,
has been a standard meta‐analysis method in GWASs
(Evangelou & Ioannidis, 2013). However, even though P
values from fastSPA and Firth’s test are well calibrated in a
single study, combining them through Z‐score method can
fail to control for Type I errors. Ma et al. (2013) has shown
that combining Firth’s test‐based P values through Z‐score
method can produce conservative or anticonservative
behaviours especially when the case–control ratio is
unbalanced and the variant minor allele count (MAC) is
small. This may be because the study‐specific P values have
discrete distribution due to case–control imbalance and small
MAC. As shown in our simulation studies, the same problem
also occurs in the meta‐analysis using fastSPA‐based P
values. To facilitate the meta‐analysis of the biobank‐based
GWASs, we need a robust method to control for Type I
errors regardless of case–control ratios and MAC.
In this paper, we first evaluate the performance of
the Z‐score‐based meta‐analysis procedure using the fastSPA
test‐based P values under extensive simulation settings and
real data sets, and propose two alternative meta‐analysis
strategies to obtain well‐calibrated meta‐analysis P values.
The first method involves sharing the overall number of
homozygous minor and heterozygous genotypes for each
genetic variant, in addition to the case–control sample size
and P value shared in the Z‐score‐based meta‐analysis
strategy. The second method involves sharing the observed
within‐study score statistics and the cumulant generating
functions (CGF) of those score statistics using a spline‐based
approach, which will be used to carry out SPA to obtain the
meta‐analysis P value. The additional information facilitates
approximating the distributions of the study‐specific score
statistics, which can be discrete, asymmetric and different
from the traditionally used normal distribution. Through
extensive simulation studies and an analysis of the UK
Biobank data, we show that the proposed methods can
control the Type I error rates and retain similar power as a
joint analysis as well as being scalable to large‐scale
PheWASs.
2 | METHODS
2.1 | Model for single study association
test and SPA
We consider J case–control studies, where the jth study
has sample size nj. Within each individual study, we
follow the regression model and testing procedure
described in Dey et al. (2017). For the ith subject in the
jth study, let Y = 1i j( ) or 0 denote the case–control status,
Xi j( ) denote the k × 1 vector of nongenetic covariates
(including the intercept) and G = 0, 1, 2i j( ) denote the
number of minor alleles of the variant to be tested. Let
β j( ) be the k × 1 vector of coefficients for the nongenetic
covariates and γ j( ) be the genotype log odds ratio. We use
the following logistic regression model to perform
association test in the jth study.
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Let μˆi j( ) be the maximum likelihood estimator of
μ Y X= Pr( = 1| )i j i j i j( ) ( ) ( ) under the null hypothesis H :0
γ = 0j( ) . Further, let X X X= ( ,…, )j j nj( ) 1( ) ( )T j
T
be the n k×j
matrix of covariates, G G G= ( ,…, )j j nj T( ) 1( ) ( ) be the genotype
vector,W j( ) be a diagonal matrix with ith diagonal element
μ μˆ (1 − ˆ )i j i j( ) ( ) , and G G X˜ = −j j j( ) ( ) ( ) X W X( )j j j( ) ( ) ( ) −1T
X W Gj j j( ) ( ) ( )T be the covariate‐adjusted genotype vector.
Then, the score statistic for testing H γ: = 0j0 ( ) will be
∑S G Y μ= ˜ ( − ˆ )j in i j i j i j( ) =1 ( ) ( ) ( )j . To apply the SPA‐based score
test, we first need to calculate the CGF of the score statistic
and its first and second derivatives given by
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Using the SPA method (Barndorff‐Nielsen, 1990;
Daniels, 1954), the distribution function of S j( ) at the
observed score statistic s can be approximated by
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where w t ts K t= sgn(ˆ) 2(ˆ − (ˆ))j( ) , v t K t= ˆ ′′ (ˆ)j( ) , tˆ is
the solution to the equation K t s′ (ˆ) =j( ) , and Φ is the
standard normal distribution function. The fastSPA (Dey
et al., 2017) test implements a faster version of this SPA
method, which can be applied to obtain the P value p j( ).
One of the steps implemented in the fastSPA test is to
apply the SPA method only if the score statistic lies
outside a certain standard deviation (SD) threshold from
the mean. If the score statistic lies inside the SD
threshold, then the fastSPA test uses the normal
approximation to calculate the P values because the
normal approximation behaves well near the mean. In
this paper, we will consider the P values using two such
SD threshold, 2 and 0.1, and will denote the tests by
fastSPA‐2 and fastSPA‐0.1, respectively.
2.2 | P value‐based meta‐analysis and
normal distribution‐based Z‐score
method
We first introduce a framework for P value‐based meta‐
analysis. In this framework, the study‐specific P values
p s( )j( ) are inverted to obtain the signed scores R sj( ) using
some distributions F j( )s, for j J= 1,…, , where the signs are
determined by the directions of associations. We call F j( )s
reference distributions. Then, the meta‐analysis score is
given by ∑R R= jJ jmeta =1 ( ) where each R F~j j( ) ( ) under
the null hypothesis of no association. Traditional Z‐score‐
based meta‐analysis is a special case of this framework,
where the reference distributions are normal distributions
with means zero and variances given by the effective
sample sizes of the individual studies. The effective sample
size (Han & Eskin, 2011) is calculated as n n n n= 4 /*j j j j1 0 ,
where nj1 and nj0 are the number of cases and controls in
the jth study, respectively. This meta‐analysis method first
inverts the P values using a standard normal distribution to
obtain the signed Z scores Z p= ±Φ ( /2)j j( ) −1 ( ) , where the
signs depend on the directions of associations. Then, the
scores R j( )s are calculated as R n Z= *j j j( ) ( ), for j J= 1,…, ,
and the meta‐analysis score is given by
∑ ∑( )R R N n= ~ 0, *jJ j jJ jmeta =1 ( ) =1 under the null hypoth-
esis. We can test the null hypothesis of no association
between the phenotype and the variant by testing
∑Z R n= / *jJ jmeta meta =1 , which follows N (0, 1) under
the null hypothesis.
This meta‐analysis strategy can control for Type I error
rates when each study‐specific P value follows the uniform
distribution. When the case–control is unbalanced and
variants are rare, however, each study‐specific test statistic
S j( ) can have a discrete and often very skewed null
distribution, which can result in the set of possible study‐
specific P values to be discrete, and the two‐sided
probabilities that constitute those P values, to be asymmetric.
In such situations, although SPA can be applied to control
Type I error rates within each individual study, inverting
such SPA‐based P values to normally distributed Z scores
might not be appropriate, and can introduce systematic bias.
We notice that the best possible reference distribution F j( )
would be the null distribution of the score statistic S j( ) under
Model (2.1) (let it be F˜ j( )). In that case, R j( )s will be the same
as S j( )s. Within each individual study, F˜ j( ) can be
approximated based on the CGF of the score statistic, using
the SPAmethod. However, it is difficult to share the CGFs as
summary level statistics. In our first method, we suggest
sharing the overall genotype counts (GCs) from the
individual studies to construct our reference distributions.
For the second approach, we propose a simpler technique to
approximate F˜ j( )s using summary level statistics and suggest
sharing S j( )s instead of the P values so that we can directly
use R S=j j( ) ( ). This is equivalent to a P value‐based meta‐
analysis using the approximations of F˜ j( )s as the reference
distributions F j( )s, because R j( )s will closely approximate S j( )s
when F j( )s closely approximate F˜ j( ). Although our ap-
proaches require more information than just the P values,
case–control sample sizes and directions of associations, the
additional information is also summary level information
and hence does not need individual level data.
2.3 | GC‐based method
Here we propose a practical approach to approximate the
CGFs using the GCs (number of 0, 1, and 2 genotypes) at
different markers. For rare variants where homozygous
minor genotypes are usually not present in the data, or
for variants that follow Hardy–Weinberg equilibrium,
sharing only the MACs will be sufficient, as the GCs can
be easily calculated based on the MACs.
Suppose, for the jth study, the GCs for the variant to
be tested are m m,j j0 1, and mj2 m m m n( + + = )j j j j0 1 2
corresponding to the genotypes 0, 1, and 2, respectively.
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Then, we can construct the genotype vectorG *j( ) of length nj
where the firstmj2 elements are 2s, nextmj1 elements are 1s,
and the rest are 0s. We propose using the null distribution
(let it be F *j( ) ) of the score statistic in the following genotype‐
only Model (2.2) as our reference distribution,
[ ( )]Y G α γ Glogit Pr = 1| = + ,* * * *i j i j j j i j( ) ( ) ( ) ( ) ( ) (2.2)
whereG *i j( ) is the ith elements ofG *j( ) , α *j( ) is the intercept,
and γ *j( ) is the genotype log odds ratio. Intuitively, when
the nongenetic covariates are relatively balanced across
cases and controls, the discreteness and asymmetry in the
null distribution of the score statistic mainly depend on the
imbalance or the rarity of the phenotype and the genotype.
Therefore, the null distribution of the score statistic under
the genotype‐only model can be a reasonable alternative to
the traditionally used normal distribution, as a reference
distribution. To apply this method, we first need to calculate
the CGF of the score statistic and its first and second
derivatives in the genotype‐only Model (2.2) given by
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where G G G= − ¯* * *i j i j j( ) ( ) ( ) is the mean‐centred geno-
types, and μˆ =*j( ) the proportion of cases, is the maximum
likelihood estimator of μ Y= Pr( = 1)*j i j( ) ( ) under the
null hypothesis H γ: = 0* *j0 ( ) . Based on this CGF, we can
approximate the distribution F *j( ) and calculate the score
R j( ) by inverting F *j( ) at the signed fastSPA P value, p± j( ),
which is calculated from the Model (1.1) with all
covariates. Since the signed P values have one‐to‐one
relationships with the score values, the inversion of p± j( )
to obtain the score R j( ) can be performed using root‐
finding algorithms such as Newton–Raphson (Press,
Flannery, Teukolsky, & Vetterling, 1992), Brent (Brent,
1973), bisection (Press et al., 1992), and so forth. In our
implementation, we applied Brent’s method for this
purpose. The meta‐analysis score ∑R R= jJ jmeta =1 ( ) will
then have the CGF ∑K K= *jJ jmeta =1 ( ) , and we can apply
the SPA test on Rmeta to obtain the meta‐analysis P value.
2.4 | CGF sharing‐based method
The aforementioned GC sharing‐based method assumes
relatively balanced covariates, which have little effect on
the discreteness and asymmetry of the null distribution of
the score statistics. A more general and mathematically
appropriate approach would be to share and utilise the
whole CGFs of the within‐study score statistics for
constructing the reference distribution. Since sharing a
complicated function like a CGF using only summary
statistics is very difficult, we propose to share the
function only at some node‐points, and reconstruct the
function at the meta‐analysis stage using spline approx-
imations. Detailed methodology for this approach is
provided in Appendix A in Supporting Information
Materials A.
2.5 | Software implementation
We implemented all our proposed methods and the
Z‐score‐based method in our R package SPAtest
(available on CRAN). The software can be used to
perform fastSPA or Score test and prepare summary level
information relevant to the different meta‐analysis
methods, as well as to perform the final meta‐analysis.
The software can also perform a hybridised meta‐analysis
based on the availability of different kinds of summary
level information. For example, suppose one study
provides only the P value and direction of association, a
second study additionally provides the GCs or MAC (if it
is a rare variant), and a third study provides the score
statistic and spline‐based information. Then, a hybrid
meta‐analysis approach will be to use a normal reference
distribution for the P value from the first study, and a
reference distribution‐based on the genotype‐only model
for the P value from the second study to calculate the
converted scores and their corresponding CGFs. The CGF
of the score statistic in the third study can be
reconstructed based on spline approximation. Then,
the final meta‐analysis score will be the sum of those
individual scores, and the corresponding CGF will be the
sum of those individual CGFs. The meta‐analysis
P value can then be obtained using the SPA method.
2.6 | Numerical simulations
We evaluated the Type I error rates and empirical powers
of the Z‐score‐based and proposed methods through
extensive simulation studies. We considered three
different simulation study settings. For the first setting,
we meta‐analysed seven studies coming from the same
population where the genotypes and the nongenetic
covariates are simulated independently. For the second
setting, we considered a meta‐analysis of seven studies
where the genotypes and the nongenetic covariates were
simulated based on the MAF and principal component
(PC) scores in different ethnic groups in the UK Biobank
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data. In the third setting, we assessed the performance of
the methods when a smaller but balanced case–control
study is meta‐analysed along with a small number of
larger but unbalanced biobank‐based studies.
2.6.1 | Simulation Study 1
Our first simulation study was designed to represent a
meta‐analysis of multiple studies from the same popula-
tion. We considered seven studies with sample sizes
nj= 2,000 for all j = 1,…,7. We further considered three
case–control ratios: balanced with the case–control ratio
of 1:1 within each study, moderately unbalanced with the
case–control ratio of 1:9 within each study, and extremely
unbalanced with the case–control ratio of 1:49 within
each study. For each choice of case–control ratio, the
phenotypes in the jth study were simulated using the
following logistic model:
[ ( )] ( )Y α X X
G γ i n
logit Pr = 1 = + 0.5 × +
+ for = 1, 2, … , ,
i
j j j j
i
j j
j
( ) ( )
1
( )
2
( )
( ) ( )
(3.1)
where X N~ (0, 1)j1( ) and X ~Bernoulli(0.5)j2( ) were the
nongenetic covariates, and the genotypes (Gi j( )s) were
generated from a pBinomial (2, ) distribution where p
(same across the seven studies) was the MAF. The intercepts
(α j( )s) were selected such that the prevalence within each
study would become 0.01. The parameters γ j( )s represent the
within‐study log odds ratios. For the Type I error
comparisons, all γ j( )s were set to be 0. A wide range of γ j( )
values were used for the power calculations (see Section 3).
To compare the Type I error rates of different methods
under different MAFs, we considered five different MAFs,
p = 0.001, 0.005, 0.01, 0.05, 0.1, and simulated 5 × 108
variants for each of the MAFs and the three case–control
ratios. We recorded the number of rejections at
α = 5 × 10−5 and 5 × 10−8 genome‐wide significance
levels. We further performed a power comparison with
5,000 simulated variants for each of the three case–control
ratios and two choices of the MAF, p = 0.01 and 0.05, at
different values of γ j( ). As the genome‐wide significance
threshold for power calculations, we used both a nominal
α = 5 × 10−8, and a Type I error adjusted empirical α
where the corresponding method has Type I error
5 × 10−8. The empirical α level was calculated based on
5 × 108 simulated data sets from the simulation setting
described above (seven studies, each with 2,000 samples)
where the MAFs were sampled from the MAF spectrum
(Figure S2 in Supporting Information Material A) of the
white British ancestry group (~117 k samples) in the UK
Biobank interim release data.
2.6.2 | Simulation Study 2
Our second simulation study was designed to represent a
trans‐ethnic meta‐analysis, where contrary to the first
simulation study setting, we not only allow the MAFs to
be different across the studies, but also simulate the
genotypes in a way such that they are correlated with the
covariates to adjust for. We considered seven studies with
sample sizes nj=2,000 for all j = 1,…,6, and n7=1,500. To
simulate the genotypes and the nongenetic covariates from
a realistic meta‐analysis of GWAS, we used genotype data
from the UK Biobank interim release data (UK Biobank,
2015). The first five studies included first four PC scores as
covariates and genotypes simulated from the MAF
spectrum of the white ancestry group in the UK Biobank
samples. To maintain the correlated nature of the genotypes
and the PC scores, genotypes were simulated using PC
scores. We further added a binary covariate generated from
a Bernoulli (0.5) distribution independent of the PC scores
and the genotypes. Covariates and genotypes were simu-
lated in a similar way for Studies 6 and 7 based on the south
Asian and black ancestry groups, respectively. The model to
simulate the phenotypes was similar to the one used in the
first simulation study, except for different nongenetic
covariates. Detailed explanation of the simulation proce-
dure is provided in Appendix B in Supporting Information
Material A.
In Transethnic studies, variants have different MAFs
across different ancestry groups. To calculate the Type I error
rates for diverse scenarios of MAFs, we first considered three
MAF bins for the alleles of the simulated variants: rare
variants with MAF<0.01, low frequency variants with
0.01<MAF<0.05 and common variants with MAF>0.05.
We then categorised the simulated variants in the following
four categories based on their allele frequencies (AF): (a) all
rare, when the variant has the same minor rare allele in all
seven studies, (b) all low frequency, when the variant has the
same low frequency allele in all seven studies, (c) all
common, when the variant has the same common allele in
all seven studies, and (d) different AF, when the variant falls
in different MAF bins in at least two different studies. The
different AF category also includes variants which have
different alleles as the minor alleles in different studies. For
each variant category and case–control ratio, we simulated
5 × 108 data sets under the null hypothesis and recorded the
number of rejections at the genome‐wide significance levels
α = 5 × 10−5 and 5 × 10−8.
2.6.3 | Simulation Study 3
We investigated the performance of different meta‐analysis
strategies when a balanced case–control study, which is
smaller in sample size, is meta‐analysed along with two
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larger biobank‐based unbalanced studies. This simulation
study represents the real‐world meta‐analyses where the
researchers collect balanced case–control data on rare
traits/diseases, and attempt to meta‐analyse them with
association results from a small number of larger cohort‐
based studies. To simulate the genotypes, nongenetic
covariates and the phenotypes, we used the same simula-
tion and logistic regression models as in our first simulation
study setting. The sample size for the balanced case–control
study was 2,000 with 1,000 cases and 1,000 controls, and the
unbalanced studies had sample size 10,000 each. We
considered two case–control ratios for these unbalanced
studies: moderately unbalanced with case:control = 1:9
within each study, and extremely unbalanced with case:
control = 1:49 within each study. For each of the case–
control ratio, we compared the Type I error rates of
different methods under five different MAFs,
p = 0.001, 0.005, 0.01, 0.05, and 0.1 based on 5 × 108
simulated variants each.
For the first two simulation settings and the unbalanced
studies in the third simulation setting, the within‐study
P values were calculated using the traditional score test
(score), fastSPA test with 2 SDs threshold (fastSPA‐2), and
fastSPA test with 0.1 SDs threshold (fastSPA‐0.1). Since
score test is relatively well‐calibrated for balanced case–
control studies (Dey et al., 2017), only score P values were
calculated for the balanced study in the third simulation
setting. We then considered the following meta‐analysis
methods to compare their Type I error rates and empirical
powers: Z‐score‐based meta‐analysis (Z score), GC sharing‐
based meta‐analysis (GC), and CGF sharing‐based meta‐
analysis (CGF‐Spline). Score P values were meta‐analysed
using the Z‐score method, fastSPA‐2 and ‐0.1 P values were
meta‐analysed using both the Z‐score and GC methods, and
the within‐study observed score statistics were meta‐
analysed using the CGF‐Spline method. For the balanced
case–control study in the third simulation setting, the Z
scores obtained from the score P values were used in the GC
method, and the corresponding normal distribution‐based
CGFs were used in the CGF‐Spline method. We also
compared the Type I error rates and the empirical powers of
a joint analysis (Joint) using the fastSPA‐2 test on the pooled
data as the gold standard. We further provided a computa-
tion time comparison of our proposed methods in Appendix
C in Supporting Information Material A.
2.7 | UK biobank data analysis
We demonstrated the performance of our proposed
methods by analysing two phenotypes based on the UK
Biobank interim release data (UK Biobank, 2015). The UK
Biobank (Bycroft et al., 2017) contains detailed phenotypic
information based on EHRs for ~500 k individuals in the
United Kingdom. In the interim release (May 2015),
information on ~150 k individuals were released to the
public. Details about the data and preprocessing are
provided in Appendix D in Supporting Information
Materials A. A histogram of the case–control ratios
(Figure S1 in Supporting Information Materials A) of
different binary phenotypes shows that the ratios are
heavily skewed towards zero, which means the binary
phenotypes are mostly unbalanced.
To compare our proposed methods with the Z‐score‐
based meta‐analysis method, we analysed two phenotypes,
ulcerative colitis (PheWAS code: 555.2, case:control≈ 1:100),
and psoriasis (PheWAS code: 696.4, case:control≈ 1:165)
based on 117,494 unrelated samples from the White British
ancestry group of the interim release data. The samples were
then divided into 22 groups based on the assessment centre
where they first consented to be included in the biobank.
We selected 19 centres (Table S1 in Supporting Information
Material A) with at least five cases for each of the two
phenotypes, and treated these centres as our individual
studies to perform association analyses of the phenotypes on
the autosomal variants within each of them. For the within‐
study association analyses, we applied fastSPA‐2, fastSPA‐
0.1 and Score tests, adjusting for age, sex, genotyping array,
and first four principal components. Individuals which had
phenotype or at least one covariate information missing,
were removed from the analysis of that corresponding
phenotype. We only applied the within‐study tests for
variants with within‐study MAC at least three. Because the
GC‐based meta‐analysis requires the overall GCs, we applied
our within‐study tests on the best called genotypes instead of
dosages in the imputed data. We then meta‐analysed the
results using the Z‐score‐based meta‐analysis (Z score), GC
sharing‐based meta‐analysis (GC), and CGF sharing‐based
meta‐analysis (CGF‐Spline). The meta‐analysis methods
were only applied for variants that were tested in at least
two different studies, and the overall MACs were at least
ten. For each phenotype, ~29 million variants were meta‐
analysed. We further performed a joint analysis (Joint) with
the pooled samples using the fastSPA‐2 test, adjusting for
the assessment centre. Due to the computational burden of
performing a pooled joint analysis, we only performed it
for the variants with GC–fastSPA‐2 P values smaller
than 5 × 10−3. Otherwise, we recorded the P values from
GC–fastSPA‐2 method as the joint analysis P values.
3 | RESULTS
In this section, we evaluate the performance of the
proposed methods against the Z‐score‐based meta‐analy-
sis based on the numerical simulations and the UK
Biobank data application described above.
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3.1 | Numerical simulations
3.1.1 | Type I error comparison
The Type I error comparison based on simulation Study 1
(Figure 1) clearly shows that the proposed CGF‐Spline and
GC methods provided well‐controlled Type I error rates
across all the MAFs and all the case–control ratios.
Expectedly, the joint analysis also controlled the Type I
error rates. In contrast, the Z‐score method resulted in
inflated Type I error rates in moderately unbalanced and
extremely unbalanced settings, especially for the rarer minor
AF. Interestingly, the Z‐score method with fastSPA‐0.1
performed worse than that with fastSPA‐2, although
fastSPA‐0.1 used the SPA to more variants. This further
verifies our assertion that using normal distributions to invert
the study‐specific P values which are possibly discrete,
asymmetric, and originally calculated using the SPA, can
result in failure to control Type I error in the meta‐analysis
process. In contrast, the GC method shows similar
performance using fastSPA‐0.1 and fastSPA‐2 P values,
which shows its robustness in meta‐analysing P values
regardless of whether they were originally calculated using
the normal approximation or the SPA. For MAF=0.001
under the extremely unbalanced setting, there is conservative
behaviour shown by the Z‐score method when using
fastSPA‐0.1 or fastSPA‐2 P values at α = 5 × 10−5 level.
All methods provided well‐controlled Type I error rates for
the balanced case–control ratio. We further simulated
5 × 108 data sets under the settings of simulation Study 1
with a much more extreme case–control ratio (1:99), and
even under such extreme case–control imbalance, our
proposed methods showed well‐controlled Type I errors,
whereas the Z‐score method overall resulted in Type I error
inflation (Figure S3 in Supporting Information Material A).
FIGURE 1 Type I error comparison between the Z‐score‐based meta‐analysis and our proposed CGF‐Spline and GC methods where the
phenotypes, nongenetic covariates, and the genotypes are simulated as described in simulation Study 1. Joint represents the joint analysis
with the pooled data. The top and the bottom panels show empirical Type I error rates at genome‐wide significance levels α = 5 × 10−5 and
5 × 10−8, respectively. From left to right, the plots consider the within‐study case–control ratios 1:1, 1:9, and 1:49, respectively. In each plot,
the X‐axis represents MAFs with expected MACs per study in parenthesis, and the Y‐axis (in logarithmic scale) represents the empirical
Type I error rates. 95% confidence intervals at different MAFs are also presented. CGF: cumulant generating function; GC: genotype count;
MAC: minor allele count; MAF: minor allele frequency
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Similar observation follows for simulation Study 2. The Type
I error comparison (Figure 2) suggests that our proposed
methods showed no sign of Type I error inflation across
different MAFs and case–control ratios, whereas the Z‐score
method resulted in inflated Type I error rates for the
moderately unbalanced and extremely unbalanced settings,
especially for the all rare, all low frequency and different
MAF categories. Z‐score method using Score P values had
the maximum inflation across all categories.
In simulation Study 3, we also have similar results
(Figure 3) for our proposed methods. However, the Z‐score
method using the fastSPA‐0.1 or fastSPA‐2 P values showed
no sign of significant Type I error inflation in the extremely
unbalanced case–control setting, and only slight inflation in
the moderately unbalanced setting. This suggests that the Z‐
score‐based method can be adequate for controlling the
Type I error rates when only a small number of biobank‐
based studies are included in the meta‐analysis. However, as
seen from the other two simulation studies, the Z‐score
method may fail to control Type I error rates when large
number of unbalanced studies are involved.
3.1.2 | Power comparison
Next, we compare the empirical powers of different meta‐
analysis strategies along‐with the joint analysis as the
gold standard under the first simulation setting. Because
the Z‐score‐based meta‐analysis method provided inflated
Type I error rates as seen in the Type I error comparisons, we
used empirical α levels calculated from Type I error
simulations for each method where the empirical Type I
error rate becomes 5 × 10−8. The power curves (Figure 4)
show that the Z‐score method has slightly lower power
(lowest when using score test P values) in the moderately
FIGURE 2 Type I error comparison between the Z‐score‐based meta‐analysis and our proposed CGF‐Spline and GC methods where the
phenotypes, nongenetic covariates, and the genotypes are simulated as described in simulation Study 2. Joint represents the joint analysis
with the pooled data. The top and the bottom panels show empirical Type I error rates at genome‐wide significance levels α = 5 × 10−5 and
5 × 10−8, respectively. From left to right, the plots consider the within‐study case–control ratios 1:1, 1:9, and 1:49, respectively. In each plot,
the X‐axis represents different MAF groups: rare (variant is rare in all studies), low frequency (variant is low frequency in all studies),
common (variant is common in all studies), and different AF (variant is in different allele frequency group in at least two different studies).
The Y‐axis (in logarithmic scale) represents the empirical Type I error rates. 95% confidence intervals at different MAFs are also presented.
AF: allele frequencies; CGF: cumulant generating function; GC: genotype count; MAF: minor allele frequency
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and extremely unbalanced case–control ratios. Our proposed
methods provide very similar power to the joint analysis, and
all methods provide similar power in the balanced case–
control setting. When nominal α = 5 × 10−8 level was used
(Figure S4 in Supporting Information Material A), the
Z‐score method expectedly showed higher powers in the
unbalanced settings as it is not calibrated for its Type I errors.
3.2 | UK biobank data analysis
We meta‐analysed the results from 19 individual
studies (assessment centres) for the phenotypes
ulcerative colitis and psoriasis, using the Z‐score‐based
meta‐analysis (Z score), GC sharing‐based meta‐
analysis (GC), and CGF sharing‐based meta‐analysis
(CGF‐Spline). The quantile–quantile (QQ) plots pre-
sented in Figures 5 and 6 show that the meta‐analysis
P values from our proposed methods closely follow the
uniform distribution, whereas those from the Z‐score
method are either much smaller (Z‐score method using
Score or fastSPA‐0.1 P values) or larger (Z‐score
method using fastSPA‐2 P values) than expected for
rare variants (MAF < 0.01). This suggests conservative
behaviour of the Z‐score method when using the
fastSPA‐2 P values, and extremely anticonservative
behaviour when using fastSPA‐0.1 or Score P values. In
FIGURE 3 Type I error comparison between the Z‐score‐based meta‐analysis and our proposed CGF‐Spline and GC methods where the
phenotypes, nongenetic covariates, and the genotypes are simulated as described in simulation Study 3. Joint represents the joint analysis
with the pooled data. The top and the bottom panels show empirical Type I error rates at genome‐wide significance levels α = 5 × 10−5 and
5 × 10−8, respectively. The left and right panels consider the within‐study case–control ratios 1:9 and 1:49, respectively for the unbalanced
studies. In each plot, the X‐axis represents MAFs with expected MACs in parenthesis, and the Y‐axis (in logarithmic scale) represents the
empirical Type I error rates. 95% confidence intervals at different MAFs are also presented. The empirical Type I error rates were almost
identical between Z score–fastSPA‐2 and Z score–fastSPA‐0.1, and between GC–fastSPA‐2 and GC–fastSPA‐0.1, and hence the lines are
sometimes overlapped in this plot. CGF: cumulant generating function; GC: genotype count; MAF: minor allele frequency; SPA: saddlepoint
approximation
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contrast, both the GC and CGF‐Spline methods
improve the accuracy of the meta‐analysis P values
and provide well‐calibrated QQ plots. Further, the QQ
plots from our proposed methods show similar
behaviour to the QQ plots from the Joint analysis
(Figure S5 in Supporting Information Material A). We
also presented the genomic control inflation factors (λ)
of different meta‐analysis strategies in Table S2 in
Supporting Information Material A. For ulcerative
colitis, all our proposed methods showed no inflation
or deflation in the genomic controls at P value
quantiles q = 0.01 and 0.001, whereas the Z‐score
method showed severely inflated inflation factors when
using the score (e.g., λ = 1.34 at q = 0.01) and fastSPA‐
0.1 (e.g., λ = 3.16 at q = 0.01) P values and deflated
inflation factors when using the fastSPA‐2 (e.g.,
λ = 0.82 at q = 0.01) P values at those P value
quantiles. This result further supports the observations
made from the QQ plots. When considering the
inflation factors at the median P value quantile
(q = 0.5), the CGF‐Spline (λ = 0.74), and GC method
using fastSPA‐2 P values (λ = 0.84) showed deflated
inflation factors, and GC method using fastSPA‐0.1
P values (λ = 1.40) showed inflated inflation factor.
This is expected, since the SPA test P values near the
median are not calculated using the SPA as discussed
in Dey et al. (2017). In that paper, they also found
inflated genomic control factors for fastSPA‐0.1 and
deflated genomic control factors for fastSPA‐2 P values
at the median level for extremely unbalanced case–
control ratios. The inflation factors showed similar
patterns for psoriasis. However, at P value quantile
q = 0.001, the GC method using fastSPA‐2 P values, and
the CGF‐Spline method showed slightly larger than
expected inflation factors (λ = 1.10 for both methods).
This might be due to the presence of the major
histocompatibility complex (MHC) in the 6p21 region
which contains a large number of polymorphic variants
and it is a known associated region for psoriasis (Stuart
et al., 2015). After excluding the MHC region from the
inflation factor calculation, the inflation factors be-
came very close to unity.
The top genome‐wide significant single‐nucleotide
polymorphisms (SNPs) in different regions, identified by
the CGF‐Spline method, are listed in Table S3 in
Supporting Information Material A. The top significant
SNPs were identical for the GC method. The P values for
the top significant SNPs were similar for all the
FIGURE 4 Power curves for the Z‐score, CGF‐Spline, and GC methods. Top panel considers MAF= 0.01 and bottom panel considers
MAF= 0.05. From left to right, the plots consider case–control ratios 1:1, 1:9, and 1:49, respectively. In each plot the X‐axis represents
genotype odds ratios and the Y‐axis represents the empirical power. Empirical power was estimated from 5,000 simulated data sets at their
Type I error adjusted empirical α levels where their empirical Type I errors are equal to 5 × 10−8. CGF: cumulant generating function;
GC: genotype count; MAF: minor allele frequency; SPA: saddlepoint approximation
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FIGURE 5 QQ plots for ulcerative colitis based on the UK Biobank interim release data. QQ plots using the Z‐score method are
provided in the left panel, and the QQ plots using our proposed methods are provided on the right panel. The plots are colour‐coded based
on different MAF categories. MAF: minor allele frequency; QQ: quantile–quantile; SPA: saddlepoint approximation
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FIGURE 6 QQ plots for psoriasis based on the UK Biobank interim release data. QQ plots using the Z‐score method are provided in the
left panel, and the QQ plots using our proposed methods are provided on the right panel. The plots are colour‐coded based on different MAF
categories. MAF: minor allele frequency; QQ: quantile–quantile; SPA: saddlepoint approximation
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methods, except Z‐score‐based meta‐analysis using
Score and fastSPA‐0.1 P values. Z‐score method using
score P values resulted in much smaller meta‐analysed
P values for all of those SNPs, and Z‐score method using
fastSPA‐0.1 P values resulted in surprisingly large
P values for testing psoriasis on the two SNPs on
chromosome 22 (rs549956609 and rs560106765). All
other meta‐analysis procedures and the joint analysis on
these two SNPs resulted in P values which were close
to the genome‐wide significance level (GC–fastSPA‐2,
CGF‐Spline, and Joint analysis P values smaller than,
and GC–fastSPA‐0.1 and Z‐score–fastSPA‐2 P values
larger than α = 5 × 10−8 level.).
3.2.1 | Applicability on imputed dosages
To assess the performance of our methods with
genotype dosage data, we further performed our with-
in‐study tests to calculate the P values, scores and
spline‐based summary statistics using the dosage data,
and then meta‐analysed the results using our proposed
methods. For the GC method, we calculated the within‐
study P values based on the dosages, but constructed the
genotype‐only model using GCs calculated using three
methods: counting the best‐called genotypes (BCG),
rounding off the dosages to the nearest integers and
counting them (rounded dosages), and GCs obtained
from the MACs assuming Hardy–Weinberg equilibrium
(HWE). We also compared the results with a joint
analysis performed in the same way described for
the genotype data analysis. The resulting QQ plots
(Figure S6–S8 in Supporting Information Material A)
showed no sign of inflation or deflation for the GC
methods, and showed very similar behaviour to the QQ
plots from the CGF‐Spline method and the Joint
analysis (Figure S9 in Supporting Information Material
A). which suggests that the methods are robust for the
analysis of dosage data.
We further generated the QQ plots for four different
ranges (<0.3, 0.3–0.6, 0.6–0.9, and ≥0.9) of imputation
quality Impute‐INFO scores (Howie, Donnelly, &
Marchini, 2009; Supporting Information Material B).
Overall, our proposed methods provided close to
uniform QQ plots. For variants with smaller INFO
scores (INFO < 0.6), the GC method using fastSPA‐0.1 P
values showed small amount of inflation when the BCG
or rounded dosage values (rounded dosage) were used.
However, GC method using only MAC information
provided the most calibrated (close to the uniform
distribution) QQ plots. This is expected, because lower
imputation quality is more often observed for rare
variants, for which MAC information is enough to
calculate the GCs, as we do not usually observe
homozygous minor genotypes.
4 | DISCUSSION
In this paper, we evaluated the performance of the
traditional Z‐score‐based meta‐analysis strategy to com-
bine association results from multiple unbalanced
GWASs, and proposed two alternative strategies that
can provide well‐calibrated meta‐analysis P values, even
when the case–control ratios are extremely unbalanced
and the MACs are small. Through extensive numerical
studies and an application on the UK Biobank data, we
showed that the Z‐score‐based method can result in
conservative or anticonservative behaviour in the meta‐
analysis P values, whereas our proposed methods
provided well‐controlled Type I error rates. The proposed
methods also showed similar empirical powers as a joint
analysis on the pooled data.
When the effect sizes are not available, such as in
the case of the SPA‐based test, it is widely popular to use
the Z‐score‐based meta‐analysis approach and combine
the individual P values into a meta‐analysis P value.
In our third simulation setting, we showed that the
Z‐score‐based approach can still be appropriate when
only a small number of biobank‐based studies with
unbalance phenotypes are included in the meta‐analysis.
However, we will suggest the researchers to be cautious
when using the Z‐score‐based approach, as including
more such unbalanced studies can result in a loss of
calibration in the meta‐analysis P values. When effect
size estimates are available, for example, when using the
Firth’s bias‐corrected likelihood ratio test (Firth, 1993),
the inverse variance‐weighted method is another popular
meta‐analysis approach used by the researchers. How-
ever, Ma et al. (2013) showed that the inverse variance‐
weighted meta‐analysis method using the Firth’s bias‐
corrected effect size estimates also results in Type I error
inflation when meta‐analysing several unbalanced
studies.
In this paper, we assumed that the individual studies
do not have genetically related samples. In presence of
related samples, the SAIGE test (Zhou et al., 2018) can
properly account for the sample relatedness and provide
accurate P values in single studies with unbalanced case–
control ratios. As the SAIGE P values are calculated
using the SPA method based on the score statistic and its
CGF, the spline‐based meta‐analysis method can still be
applicable for combining multiple studies that are
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analysed using SAIGE. However, the GC‐based method
may not be appropriate in such scenarios as the
genotype‐only model does not contain any information
about the sample relatedness. The applicability of our
methods in studies containing genetically related sam-
ples, is left for future research.
Comparing the two proposed methods, the spline‐
based method (CGF‐Spline) does not require any
assumption on the effect of the nongenetic covariates
since it reconstructs spline approximations of the null
distributions of the score statistics and uses them to
calculate the meta‐analysis P values. Thus, it is more
suitable to be applied regardless of of the covariate
effects. On the other hand, the GC‐based method (GC)
assumes relatively balanced nongenetic covariates with
low covariate effects. However, the numerical simula-
tions with very strong covariate effects (Figure S10 in
Supporting Information Material A) also showed no sign
of Type I error inflation or deflation for this method.
Another difference between the proposed methods is in
their applicability on imputed dosage data. As the GC
method requires the overall GCs to construct the
genotype‐only model, it is more suitable to be applied
when the within‐study analyses are performed on the
BCG instead of dosages. The CGF‐spline method is
robust in this aspect as it can utilise the CGFs of the test
statistics regardless of whether they were calculated from
genotype or dosage data. However, in our UK Biobank
data analysis example, both our proposed methods
showed no sign of inflation or deflation of Type I errors,
even when the within‐study tests were performed on
dosage data. Therefore, for practical application pur-
poses, the GC‐based method can be used to obtain
accurate meta‐analysis P values. One advantage of the
GC‐based method is that it is software‐independent, and
requires information which are more readily available
compared to the spline‐based method.
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